Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious ...
The other is an injection of antibodies — sold under the brand name Beyfortus, known by its scientific name nirsevimab — given to infants before their first RSV season, and a few high-risk ...
(RTTNews) - Sanofi - Aventis Groupe said that the data featured at IDWeek from several national immunization programs will reinforce the proven efficacy and favorable safety profile of Beyfortus ...